WebApr 30, 2016 · April 26, 2016 – Excerpt from NewsOk: “Through an association with William Hagstrom of Alpha Bio Partners, Branch became acquainted with OU professor Anne Pereira, Ph.D. Pereira had co-founded Biolytx Pharmaceuticals with Hagstrom based on her groundbreaking work in developing peptides that kill antibiotic resistant bacteria.” WebBiolytx Pharmaceuticals has raised a total of $1.1M in funding over 2 rounds. Their latest funding was raised on Nov 6, 2015 from a Seed round. Biolytx Pharmaceuticals is funded by 2 investors. i2i, Inc. and i2E are the most recent investors.

Startups - University of Oklahoma

WebBiolytx Pharmaceuticals, Corp. is a pharmaceutical technology company developed by Dr. Anne Pereira and the University of Oklahoma Health Sciences Center. Lists … WebBiolytx Pharmaceuticals is a pharmaceutical technology company developed by Dr. Anne Pereira and the University of Oklahoma Health Sciences Center. Still in the pre-clinical … graphite d-spacing

Antibiotic Resistance Markets, 2024 - Business Wire

WebBoard Member and Co-Founder. Mr. Hagstrom has served as a member of our Board of Directors since incorporation in 2005. He has served as the founder and CEO of Octave Bioscience, an early-stage diagnostics company focused on neurodegenerative diseases since 2014. From 2006 to 2014, Mr. Hagstrom served as president and CEO of … WebBiolytx Pharmaceuticals Corp. is developing a peptide, BP001, derived from the human endogenous host defense protein CAP37, as a novel multi-target ophthalmic product for corneal infections and injuries. The standard-of-care for corneal infections is topical administration of antibiotics that may be accompanied by topical WebBiolytx is an emerging drug development company confronting the crisis in antibiotic (AB) drug resistance through the advancement of a suite of antimicrobial peptide drug … chi scholarships